Comparison · NCT00724854-8ce3d1d8
Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants Who Achieved Sustained Virologic Response (SVR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants Who Achieved Sustained Virologic Response (SVR). Trial comparisons, record NCT00724854-8ce3d1d8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00724854-8ce3d1d8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.371 | 0.342 | 0.402 | wilson | |
| Risk in group 2 | 0.333 | 0.235 | 0.448 | wilson | |
| Risk difference, group 1 minus group 2 | 0.038 | -0.0806 | 0.14 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.796 | 1.56 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.712 | 1.96 | log | |
| Number needed to treat, for one more participant with the outcome on Mono-infected With HCV than on Co-infected With HCV and HIV | 26.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mono-infected With HCV | Participants infected with Hepatitis C Virus (HCV), received PegIntron plus Rebetol, administered in accordance with approved labeling. | 375 | 1,010 | OG000 |
| Group 2 | Co-infected With HCV and HIV | Participants co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV), received PegIntron plus Rebetol, administered in accordance with approved labeling. | 24 | 72 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Achieved Sustained Virologic Response (SVR)
- Description
- SVR was defined as non-detectable HCV RNA 24 weeks post-treatment.
- Time frame
- Assessed at 24 weeks post-treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
- NCT number
- NCT00724854
- Phases
- Conditions
- Hepatitis C, Chronic, Hepatitis C
- Interventions
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2011-01-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00724854?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00724854-8ce3d1d8